Last reviewed · How we verify
NCT05144672
Irisin And Diabetic Nephropathy
trial testing Laboratory tests in Irisin in 90 participants. Status unknown.
30 April 2023
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 90 |
| Start date | 1 January 2022 |
| Primary completion | 30 April 2023 |
| Estimated completion | 30 June 2023 |
Drugs / interventions tested
- Laboratory tests
- Anthropometric measurements
- Electrocardiogram and Fundus examination
- Estimated glomerular filtration rate (eGFR)
- Brachial index
- Laboratory tests
- Abdominal ultrasound.
Conditions studied
- Irisin — all drugs for Irisin →
Sponsor
Assiut University
Who can join
40 and older, any sex, with Irisin. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Diabetes mellitus (DM) is a complex, multifactorial, chronic metabolic and endocrine disorder. It has become a threat to global health. It has two types. It is estimated that the number of people with type II will reach 700 million by 2045.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05144672
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Laboratory tests
Trials testing the same drug.
- NCT04903912 — Campania Registry On Peripheral Artery Disease · recruiting
- NCT03952637 — A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Typ · Phase 1, PHASE2 · recruiting
- NCT03696810 — Characterization of Retinal Vascular Disease in Eyes With Mild to Moderate NPDR in Diabetes Type 2 · NA · completed
- NCT03437109 — Efficacy of Androgen Substitution for Hypogonadism in Men With Type 2 Diabetes Mellitus · completed
- NCT03182699 — Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients · Phase 4 · completed
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05144672 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 3 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05144672.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing